Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 09, 2018

SELL
$5.07 - $7.92 $1,612 - $2,518
-318 Closed
0 $0
Q2 2017

Aug 16, 2017

BUY
N/A
318
318 $2,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Mcia Inc Portfolio

Follow Mcia Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mcia Inc, based on Form 13F filings with the SEC.

News

Stay updated on Mcia Inc with notifications on news.